Technical Analysis for CYCN - Cyclerion Therapeutics, Inc.

Grade Last Price % Change Price Change
F 3.20 -1.54% -0.05
CYCN closed down 1.54 percent on Monday, March 18, 2024, on 1.46 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Up

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
20 DMA Support Bullish 0.00%
Gapped Down Weakness 0.00%
50 DMA Support Bullish -1.54%
MACD Bullish Centerline Cross Bullish -1.54%
Upper Bollinger Band Touch Strength -1.54%
200 DMA Resistance Bearish -4.76%
Crossed Above 50 DMA Bullish -4.76%
180 Bullish Setup Bullish Swing Setup -4.76%
Above Upper BB Strength -4.76%

   Recent Intraday Alerts

Alert Time
20 DMA Support about 15 hours ago
10 DMA Support about 15 hours ago
60 Minute Opening Range Breakout about 18 hours ago
Gapped Down (Full) about 21 hours ago
2x Volume Pace about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cyclerion Therapeutics, Inc. Description

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its current portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Disease Organ Systems Pharmacology Kidney Disease Heart Failure Diabetic Nephropathy Cardiomyopathy Central Nervous System Disease Orphan Disease Sickle Cell Disease Lung Diseases

Is CYCN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.036
52 Week Low 1.7501
Average Volume 2,788
200-Day Moving Average 3.36
50-Day Moving Average 3.20
20-Day Moving Average 3.05
10-Day Moving Average 3.09
Average True Range 0.29
RSI (14) 52.61
ADX 22.76
+DI 34.04
-DI 24.14
Chandelier Exit (Long, 3 ATRs) 2.82
Chandelier Exit (Short, 3 ATRs) 3.58
Upper Bollinger Bands 3.34
Lower Bollinger Band 2.75
Percent B (%b) 0.76
BandWidth 19.53
MACD Line 0.02
MACD Signal Line -0.02
MACD Histogram 0.0353
Fundamentals Value
Market Cap 7.82 Million
Num Shares 2.45 Million
EPS -18.53
Price-to-Earnings (P/E) Ratio -0.17
Price-to-Sales 7.25
Price-to-Book 0.70
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.68
Resistance 3 (R3) 3.63 3.41 3.60
Resistance 2 (R2) 3.41 3.29 3.44 3.57
Resistance 1 (R1) 3.31 3.22 3.36 3.36 3.55
Pivot Point 3.09 3.09 3.12 3.12 3.09
Support 1 (S1) 2.99 2.97 3.04 3.04 2.85
Support 2 (S2) 2.77 2.90 2.80 2.83
Support 3 (S3) 2.67 2.77 2.80
Support 4 (S4) 2.72